Merck Sharp + Dohme Corp.

Libo Xu

Songnian Lin

Emma R Parmee

Subharekha Raghavan

Brian T Campbell

Dann LeRoy Parker, Jr

Joie Garfunkle

Olga Ornoski

Andrew William Stamford

John A McCauley

Sherman Tim Waddell

Thomas H Graham

Tao Yu

Xibin Liao

Jiayi Xu

Edward Metzger

Jay A Grobler

Rui Zhang

Sunita V Dewnani

Feroze Ujjainwalla

Ping Liu

Rui Liang

John S Debenham

Helen Y Chen

Richard Berger

Timothy A Blizzard

John E Stelmach

Guizhen Dong

Timothy Allen Blizzard

Fengqi Zhang

Sheryl Davis Debenham

Zhiqiang Yang

Zhiyong Hu

Bart Harper

Zhiqiang Guo

Ming Wang

Alexander J Kim

Wensheng Liu

Zack Zhiqiang Guo

Candido Gude

Byron Dubois

Roman Kats-Kagan

Christian P Stevenson

Zhiquang Yang

Wengsheng Liu

John A Mccauley

Dann L Parker

The present invention relates to Spirocyclic Pyridotriazine Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, Y, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Pyridotriazine Derivative, and methods of using the Spirocyclic Pyridotriazine Derivatives for treating or preventing HIV infection in a subject. 

Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors

The present invention relates to Amido-Substituted Pyridotriazine Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein B, X, Y, R, RRand Rare as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Pyridotriazine Derivative, and methods of using the Amido-Substituted Pyridotriazine Derivatives for treating or preventing HIV infection in a subject. 

Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or pharmaceutically acceptable salt thereofs, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or pharmaceutically acceptable salts thereof. 

Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof. 

Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators

The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity. 

Isoquinoline derivatives as MGAT2 inhibitors

A compound of Formula II or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula II, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula II or a pharmaceutically acceptable salt thereof. 

Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators

Glucagon receptor antagonist compounds are disclosed which are of long duration of action. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Novel pyridine-2-carboxamide derivatives of formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. 

Glucokinase activator compounds, compositions containing such compounds, and methods of treatment

Glucagon receptor antagonist compounds of formula I are disclosed: The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type (2) diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Growing community of inventors

Bridgewater, NJ, United States of America

Libo Xu